| |
| Our team is taking a break over the holidays, and we'd like to highlight some of our best articles and reports. The Daily Pitch will return Jan. 4. Happy New Year! | | | | | |
| |
| Come one, come all: Crypto's wild ride in 2022 | |  | | (Leonard Zhukovsky/Shutterstock) | | | FTX founder Sam Bankman-Fried's extradition to the US caps a topsy-turvy year for crypto.
Bitcoin fell more than 60%. Bored Apes were held hostage. Larry David had the last laugh. Tens of billions of dollars in value vanished from investors' funds—not to mention users' accounts.
Here's a look back at the events that reshaped the industry. | | | | | | | | | Quiz: Did you follow private markets in 2022? | |  | | (Jenna O'Malley/PitchBook News) | | | 2022 brought drama galore to the private investment landscape.
The fallout from the war in Ukraine seemed to touch everything–even a Premier League buyout and a European startup competition. Disgraced founders were by turns arrested, sentenced and redeemed. Private equity expanded into blockchain funds and startup loans.
Our quiz has the highlights, the lowlights and everything in between. | | | | | | | |
| |
| |
| | Since yesterday, the PitchBook Platform added: | | 137 Deals | 627 People | 325 Companies | 5 Funds | | | | | | |
| |
| Europe's top 10 venture deals of 2022 | |  | | (Wetzkaz Graphics/Shutterstock) | | | Raising outsize venture rounds became increasingly difficult in 2022 as many investors pulled back from dealmaking.
Nevertheless, mega-rounds weren't in short supply this year. Check out the 10 biggest VC deals closed in Europe in 2022. | | | | | | | | | The next generation of clinical trials will be decentralized | |  | | (Nataliia Maksymenko/Shutterstock) | | | The COVID-19 pandemic spurred demand for decentralized clinical trials that could be run through telemedicine services. As the world opens back up, these trials are here to stay.
Research organizations like the format because it gives them a broader patient population and greater efficiency. In this report, Morningstar analysts lay out the benefits of decentralized trials, the major players and entry points for institutional investors. | | | | | | | |
| |
| |
| Private debt outlook 2023: Risk and opportunity co-exist | |  | | (kudla/Shutterstock) | | | While private debt deal flow and fundraising pace have slowed from last year's record highs, the industry still ended this year on solid footing. But 2023, which is expected to be a tumultuous year, will present the industry with a series of challenges.
Anticipating greater uncertainty in the economy and more rate hikes from the Federal Reserve, investors still view private debt as attractive. However, they will want more downside protections for their private credit investments in this environment. | | | | | | | |
| |
| |
No comments:
Post a Comment